Articles tagged with Pi3k Inhibitors
A combination therapy of FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel is being investigated in a Phase 2 trial for patients with advanced or recurrent endometrial cancer. The trial aims to target the PI3K/AKT/mTOR pathway, which is frequently mutated in cancer.
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
Researchers designed a molecule, MTX-531, that impairs signaling drivers of cancer therapy resistance. In mouse models, MTX-531 led to tumor regressions in multiple head and neck cancers, showing a favorable toxicity profile.
This study investigates the impact of hydrogen sulfide on platelet autophagy in cirrhotic thrombocytopenia and reveals that H2S modulates platelet autophagy via the PDGFR-alpha/PI3K/AKT signaling pathway, which may contribute to thrombocytopenia.
Mutations in the PIK3CA gene lead to elevated production of the PI3Ka protein, found in approximately 40% of hormone receptor-positive breast cancers. Next-generation PI3Kalpha inhibitors targeting a different region of the mutant protein show promise in overcoming resistance.
Researchers found that CUDC-907 selectively induces apoptosis in cells driven to senesce by p53 expression. The compound showed senolytic properties in different models of stress-induced senescence, depending on its inhibitory effects on HDACs and PI3K.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
A new review paper discusses the role of CDK4 in regulating the cell cycle and its involvement in cancer. The study highlights the importance of CDK4/6 inhibitors as treatments for ER+ breast cancer and their potential utility in multiple tumor types.
ARID1A-deficient bladder cancers are sensitive to combination therapies with the EZH2 inhibitor GSK-126 and inhibitors of PI3K, acting synergistically. The research found that tumors deficient in ARID1A protein have elevated levels of PIK3R3 and phosphoAKT.
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
Researchers at Baylor College of Medicine have identified MAPK4 as a key player in triple-negative breast cancer growth and resistance to therapies. Eliminating or inhibiting MAPK4 reduces TNBC cell growth and sensitizes cells to PI3K inhibitors.
Research reveals tamoxifen boosts PI3K signaling, potentially increasing uterine cancer risk in breast cancer patients. Preclinical studies show PI3K inhibitor alpelisib mitigates this effect.
The study found that combining mTORC1 and PLK1 inhibitors showed high antitumor activity in NSCLC, with synergistic effects observed. The combination may target specific biomarkers of resistance to Pi3K-based monotherapies, offering a promising therapeutic approach.
Research found that combining copanlisib with cetuximab significantly improves treatment outcomes in head and neck squamous cell carcinoma (HNSCC) patients. The study suggests PI3K inhibition as a potential biomarker for predicting treatment responses.
Moffitt researchers found that umbralisib, a PI3K/CK1ε inhibitor, showed fewer immune-mediated side effects compared to traditional PI3K inhibitors. The study suggests that dual inhibition may improve safety profiles for CLL patients.
A University of Colorado Cancer Center study found that tobacco use creates a field of precancerous cells that fertilize nearby cancer cells, enabling them to grow and resist therapy. The research suggests that these precancerous cells provide fuel through EGFR ligands, allowing cancer cells to bypass PI3K inhibition.
Researchers identified RB1 gene mutations as a mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for HR-positive breast cancer. The study found that these mutations led to loss of RB1 function and consequently resistance to CDK 4/6 inhibitors in patients whose tumors progressed after treatment.
Researchers have identified a connection between the PI3K pathway and telomere protection, revealing a potential target for cancer treatment. Inhibition of PI3K reduces TRF1 levels, leading to chromosome destabilization and cancer cell death.
The LORELEI trial found that adding taselisib to letrozole before surgery improved outcomes for patients with early breast cancer. Taselisib showed a significant increase in objective response rate and worked particularly well in patients with PIK3CA mutant cancer cells.
Researchers found that PI3K inhibitors reprogram the mitochondria of tumor cells, causing them to produce energy in a localized manner, leading to a more aggressive and invasive phenotype. This paradoxical response may offer a new therapeutic angle for treating cancers.
Researchers found that long-term PI3K inhibitor treatment reactivates Akt through an unknown ERK1/2 regulatory loop. This limits the effectiveness of anti-PI3K strategies against K-Ras mutant or overexpressed tumor cells. Combining MEK-ERK1/2 and PI3K inhibitors may overcome resistance in these tumors.
Researchers found that combining PI3K inhibitors with anti-HER2 therapy can prolong treatment effectiveness by targeting the PI3K pathway, which activates anti-death protein survivin. High levels of survivin correlate with resistance to therapy, suggesting its measurement could predict treatment outcomes.
Researchers testing a combination of GDC-0973 and GDC-0941, which inhibit the RAS/RAF/MEK and PI3K pathways, report encouraging safety data and early signs of anti-tumor activity. Patients with various types of cancer have shown decreases in tumor size, suggesting potential benefits for targeted therapy.
Researchers found that upregulation of HER3 receptor limits effectiveness of targeted therapies in HER2-positive breast cancers. Targeting both HER2 and HER3 together with these agents improves clinical utility. Combination therapy also shows potential in treating other cancers.
Research reveals that HGF-induced invasion of cholangiocarcinoma is mediated by distinct signaling pathways, with PI3K pathway being common and ERK1/2 playing a key role depending on activation duration. This understanding may aid in identifying therapeutic targets for individual patients.
Researchers found that combining a PI3K inhibitor with Herceptin can reverse lack of response in HER2-positive breast cancer patients. The addition of a PI3K inhibitor showed significant benefit in halting tumor growth, especially in tumors lacking PTEN protein.